We are live on ! Find out more
CPXX

CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX

Delisted

CPXX was delisted on the 11th of July, 2016.

Back to rankings

0 hedge funds and large institutions have $0 invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 117 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 119 → 0 (-119)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $944M → $0 (-$944M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 117

Holders
–
Holders Change
-119
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
117
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
-$67.4M
2
AAM
Alpine Associates Management
Florida
-$66.9M
3
MF
Magnetar Financial
Illinois
-$48M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$37.9M
5
ACA
Avoro Capital Advisors
New York
-$33.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
76
Sabby Management
Florida
– -$800K -26,500 Closed
Citadel Advisors
77
Citadel Advisors
Florida
– -$776K -25,716 Closed
State Board of Administration of Florida Retirement System
78
State Board of Administration of Florida Retirement System
Florida
– -$775K -25,685 Closed
O
79
OppenheimerFunds
New York
– -$775K -25,674 Closed
FMA
80
FNY Managed Accounts
New York
– -$758K -25,100 Closed
Capstone Investment Advisors
81
Capstone Investment Advisors
New York
– -$754K -25,000 Closed
MLICM
82
Metropolitan Life Insurance Company (MetLife)
New York
– -$729K -24,149 Closed
BA
83
BlackRock Advisors
Delaware
– -$718K -23,796 Closed
Citigroup
84
Citigroup
New York
– -$707K -23,439 Closed
Millennium Management
85
Millennium Management
New York
– -$678K -22,466 Closed
NFA
86
Nationwide Fund Advisors
Ohio
– -$646K -21,417 Closed
Manulife (Manufacturers Life Insurance)
87
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$638K -21,128 Closed
CCM
88
Cadence Capital Management
Massachusetts
– -$623K -20,630 Closed
AIG
89
American International Group
New York
– -$568K -18,804 Closed
DCM
90
Dupont Capital Management
Delaware
– -$504K -16,700 Closed
DC
91
Deere & Company
Illinois
– -$451K -14,957 Closed
VOYA Investment Management
92
VOYA Investment Management
Georgia
– -$427K -14,138 Closed
BG
93
BlackRock Group
United Kingdom
– -$409K -13,579 Closed
Wells Fargo
94
Wells Fargo
California
– -$407K -13,500 Closed
UBS AM
95
UBS AM
Illinois
– -$398K -13,200 Closed
Squarepoint
96
Squarepoint
New York
– -$380K -12,600 Closed
FWM
97
Frontier Wealth Management
Missouri
– -$377K -12,500 Closed
TI
98
Telemetry Investments
New York
– -$338K -11,200 Closed
SO
99
STRS Ohio
Ohio
– -$328K -10,900 Closed
GC
100
Guggenheim Capital
Illinois
– -$294K -9,737 Closed
1 2 3
4
5

CPXX Hedge Fund Activity: Q3 2016 in Review

0 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q3 2016, worth a combined $0 — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 117 funds closed out of CPXX and 0 opened new positions — a net loss of 117 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Caxton Corporation, exiting entirely with an estimated $67.4M sold.

  • 0 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q3 2016, down from 119 in Q2 2016.
  • Funds reported $0 of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q3 2016, down 100% quarter-over-quarter.
  • 0 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q3 2016 and 117 closed out, a net change of -117 holders.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q3 2016 was Caxton Corporation, an estimated $67.4M sold.

Based on aggregated 13F filings for Q3 2016.